57th ASH Annual Meeting and Exposition (December 5-8, 2015): 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Late Complications and Immune Evasion

Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence Oral and Poster Abstracts
Oral

W304ABCD, Level 3 (Orange County Convention Center)

Moderators:

Alison Loren, MD, MS, Abramson Cancer Center of the University of Pennsylvania and John R. Wingard, MD, University of Florida

Disclosures:

Loren: Merck: Research Funding .

2:45 PM

739

Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS)

Mukta Arora, MD, MS¹, Can-Lan Sun, PhD²^*, Kirsten K. Ness, PhD³^*, Jennifer Berano Teh, MD²^*, Jessica Wu⁴^*, Liton F. Francisco, BS⁴^*, Saro Armenian, DO, MPH², Amy Schad, MPH, CCRP²^*, Golnaz Namdar, MPH²^*, Alysia Bosworth²^*, Linus Kuo²^*, Daniel Weisdorf, MD¹, Stephen J. Forman, MD² and Smita Bhatia, MD, MPH⁵

¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²City of Hope National Medical Center, Duarte, CA
³Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
⁴Institute for Cancer Outcomes and Survivorship, University of Alabama, Birmingham, AL
⁵Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL

3:00 PM

740

Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations

Betty K. Hamilton, MD¹, Navneet S. Majhail, MD, MS¹, Cassandra M Hirsch²^*, Bartlomiej Przychodzen, MSc³^*, Lisa A. Rybicki, MS⁴^*, Marcos De Lima, MD⁵, Matt Kalaycio, MD⁶, Brian J. Bolwell, MD¹, Aaron T. Gerds, MD, MS⁷, Ronald Sobecks, MD¹, Rabi Hanna, MD⁸, Mikkael A. Sekeres, MD, MS⁹ and Jaroslaw P. Maciejewski, MD, PhD²

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
²Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁴Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH
⁵Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland
⁶Leukemia Program, Cleveland Clinic, Cleveland, OH
⁷Blood and Marrow Transplant, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁸Pediatric Hematology/Oncology, Cleveland Clinic, Cleveland, OH
⁹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3:15 PM

741

Copies of Donor Killer Immunoglobulin-like Receptor Genes and Motifs Titrate Natural Killer (NK) Cells' Functional Response to Epstein - Barr Virus Infections and Influence the Risk of Developing Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Cell Transplantation

Rehan Mujeeb Faridi, PhD¹^*, Taylor J Kemp, B.HSc¹^*, Poonam Dharmani, PhD¹^*, Victor A. Lewis, MD², Noureddine Berka, PhD, D (ABHI)³^*, Jan Storek, MD, PhD¹ and Faisal M Khan, PhD, D (ABHI)^1,4^*

¹University of Calgary, Calgary, AB, Canada
²Department of Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada
³Calgary Laboratory Services, Calgary, AB, Canada
⁴Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada

3:30 PM

742

Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Natasha Kekre, MD, MPH, FRCPC¹, Haesook T. Kim, PhD²^*, Vincent T. Ho, MD³, Corey S Cutler, MD, MPH⁴, Philippe Armand, MD, PhD⁴, Sarah Nikiforow, MD, PhD⁴, Edwin P. Alyea, MD⁴, Robert J. Soiffer, MD⁵, Joseph H Antin, MD¹, Jean M. Connors, M.D.⁶ and John Koreth, MBBS, DPhil¹

¹Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Dana-Farber Cancer Institute, Boston, MA
⁶Hematology Division, Brigham and Women's Hospital, Boston, MA

3:45 PM

743

HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics

Valentina Gambacorta, MSc¹^*, Giacomo Oliveira, PhD^1,2^*, Laura Zito, MSc¹^*, Cristina Toffalori, PhD¹^*, Lara Crucitti, MD^1,3^*, Maddalena Noviello, PhD²^*, Benedetta Mazzi, MSc¹^*, Raffaella Greco, MD³^*, Maria Teresa Lupo Stanghellini, MD³^*, Matteo G Carrabba, MD³^*, Massimo Bernardi, MD³^*, Jacopo Peccatori, MD³^*, Katharina Fleischhauer, MD⁴^*, Chiara Bonini, MD², Fabio Ciceri, MD³^* and Luca Vago, MD, PhD^1,3

¹Unit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milano, Italy
²Experimental Hematology Unit, San Raffaele Scientific Institute, Milano, Italy
³Unit of Hematology and Bone Marrow Transplantation, San Raffaele Scientific Institute, Milano, Italy
⁴Institute for Experimental Cellular Therapy, Institute for Experimental Cellular Therapy, Essen, Germany

4:00 PM

744

The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Jonathan Peled, MD, PhD¹, Eric R. Littman²^*, Lilan Ling³^*, Satyajit Kosuri, MD¹, Molly Maloy, MS¹^*, Sergio A. Giralt, MD¹, Juliet N. Barker, MBBS (Hons)¹, Miguel-Angel Perales, MD¹, Ying Taur, MD⁴^*, Eric Pamer⁴^*, Marcel van den Brink, MD, PhD¹ and Robert R. Jenq, MD¹^*

¹Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Memorial Sloan Kettering Cancer Center, New York
⁴Department of Medicine, Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, NY

See more of: Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

723.O2.6 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Late Complications and Immune Evasion